Asembia’s Specialty Pharmacy Summit

At the 2022 Asembia Specialty Pharmacy Summit, healthcare policy experts at Avalere shared insights into the politics of a less ambitious Build Back Better bill and the healthcare provisions it might include. If a "skinny bill" doesn't get passed, the healthcare action of the Biden administration might shift to CMS Innovation Center and payment models, including a successor to the Oncology Care Model, they said.

Jayne Hornung, Chief Clinical Officer, Pharmacy, MMIT addresses the difference between digital therapeutics in the pharmacy and medical benefit space, and digs into the potential causes of the slow uptake in digital therapeutics among payers during this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Doug Long, vice president of Industry Relations at IQVIA spoke on how the current inflationary trend in the economy affects healthcare spending and prices, as well as the trend of specialty drugs accounting for half of the drug spend in healthcare. Hear more of what he shared with our team at this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Tracy Russell, senior director of state government affairs at CoverMyMeds addressed what piece of new federal legislation will have the biggest effect on specialty pharmacy and what the Biden administration's emphasis on healthcare equity will do for specialty pharmacy. Russell spoke more on this topic at this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Risk Evaluation and Mitigation Strategies (REMS) programs are designed to protect patients, but they can also make providers more confident about prescribing a drug, explained panelists at the Asembia specialty pharmacy meeting. And the FDA collaborates with drugmakers on the planning the particulars of the programs, said Steve Granzyk and Tiffany Abraham.